Search

Displaying results 671 - 680 of 7062 in total
  1. Drug

    Filgrastim

    go.drugbank.com/drugs/DB00099
    ApprovedInvestigational

    [A245858] Tbo-filgrastim was approved by the FDA on August 29, 2012.[L36325] Filgrastim-sndz was approved on March 6, 2015 [L40768] and filgrastim-ayow was approved on March 2, 2022. … Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology.

    Products: ZARZIO SOLUTION FOR INJECTION/INFUSION IN A PREFILLED SYRINGE 30MU/0.5ML, ACCOFIL 30 SOLUTION FOR INJECTION OR INFUSION IN A PRE-FILLED SYRINGE 30 MU/0.5 ML
  2. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L1024] In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.

  3. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. … [L30598] It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter [A251445] and a metabolite of the inhibitory neurotransmitter GABA.

  4. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis].

    Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease Inhibitors
  5. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies

  6. Drug

    Choline

    go.drugbank.com/drugs/DB00122
    ApprovedInvestigationalNutraceutical

    It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. … A basic constituent of lecithin that is found in many plants and animal organs.

    Mixtures: One A Day Tab, Extra Once A Day
  7. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.

  8. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    [L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … The Moderna COVID-19 Vaccine (mRNA-1273; Elasomeran) is a novel mRNA-based vaccine encapsulated in a lipid nanoparticle that encodes for a full-length pre-fusion stabilized spike (S) protein of severe

    Mixtures: Spikevax Bivalent (original / Omicron Ba.4/5)
  9. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]

  10. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

    Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease Inhibitors